デフォルト表紙
市場調査レポート
商品コード
920541

IBD治療市場:世界の業界分析、規模、シェア、成長、動向、予測(2019~2027年)

IBD Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027

出版日: | 発行: Transparency Market Research | ページ情報: 英文 195 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=114.84円
IBD治療市場:世界の業界分析、規模、シェア、成長、動向、予測(2019~2027年)
出版日: 2019年11月07日
発行: Transparency Market Research
ページ情報: 英文 195 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、IBD治療市場について調査し、市場の動向と予測、市場規模、主要参入企業、地域別動向についてまとめています。

第1章 序論

第2章 仮定と調査方法

第3章 エグゼクティブサマリー

第4章 市場概要

  • イントロダクション
  • 概要
  • 市場動向
    • 促進因子
    • 阻害因子
    • 機会
  • 市場分析と予測

第5章 世界市場:主な動向

  • 治験パイプライン分析
  • 疾患罹患率
  • 主な取引・戦略的提携分析

第6章 市場分析と予測:薬剤クラス別

  • 主な調査結果
  • イントロダクション
  • 市場価値予測
    • TNF阻害剤
    • アミノサリチル酸
    • インテグリン拮抗薬
    • コルチコステロイド
    • その他
  • 市場の魅力度

第7章 市場分析と予測:疾患適応別

  • 主な調査結果
  • イントロダクション
  • 市場価値予測
    • 潰瘍性大腸炎
    • クローン病
  • 市場の魅力度

第8章 市場分析と予測:流通チャンネル別

  • 主な調査結果
  • イントロダクション
  • 市場価値予測
    • 院内薬局
    • 小売薬局
    • オンライン薬局
  • 市場の魅力度

第9章 市場分析と予測:地域別

  • 主な調査結果
  • 市場価値予測
    • 北米
    • 欧州
    • アジア太平洋地域
    • ラテンアメリカ
    • 中東・アフリカ
  • 市場の魅力度

第10章 北米

第11章 欧州

第12章 アジア太平洋地域

第13章 ラテンアメリカ

第14章 中東・アフリカ

第15章 競合環境

  • 市場シェア
  • 競合マトリクス
  • 企業プロファイル
図表

List of Tables

  • Table 01: Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017-2027
  • Table 02: Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Disease Indication, 2017-2027
  • Table 03: Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2027
  • Table 04: Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Region, 2017-2027
  • Table 05: North America IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Country, 2017-2027
  • Table 06: North America IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017-2027
  • Table 07: North America IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Disease Indication, 2017-2027
  • Table 08: North America IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2027
  • Table 09: Europe IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2027
  • Table 10: Europe IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017-2027
  • Table 11: Europe IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Disease Indication, 2017-2027
  • Table 12: Europe IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2027
  • Table 13: Asia Pacific IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2027
  • Table 14: Asia Pacific IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017-2027
  • Table 15: Asia Pacific IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Disease Indication, 2017-2027
  • Table 16: Asia Pacific IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2027
  • Table 17: Latin America IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2027
  • Table 18: Latin America IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017-2027
  • Table 19: Latin America IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Disease Indication, 2017-2027
  • Table 20: Latin America IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2027
  • Table 21: Middle East & Africa IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2027
  • Table 22: Middle East & Africa IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017-2027
  • Table 23: Middle East & Africa IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Disease Indication, 2017-2027
  • Table 24: Middle East & Africa IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2027

List of Figures

  • Figure 01: Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, 2017- 2027
  • Figure 02: Market Value Share, by Drug Class (2018)
  • Figure 03: Market Value Share, by Disease Indication (2018)
  • Figure 04: Market Value Share, by Distribution Channel (2018)
  • Figure 05: Market Value Share, by Country (2018)
  • Figure 06: Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Value Share analysis, by Drug Class, 2018 and 2027
  • Figure 07: Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Attractiveness Analysis, by Drug Class, 2019-2027
  • Figure 08: Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by TNF Inhibitors, 2017-2027
  • Figure 09: Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Aminosalicylates, 2017-2027
  • Figure 10: Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Integrin Antagonists, 2017-2027
  • Figure 11: Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Corticosteroids, 2017-2027
  • Figure 12: Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Value Share Analysis, by Disease Indication, 2018 and 2027
  • Figure 13: Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Attractiveness Analysis, by Disease Indication, 2019-2027
  • Figure 14: Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Ulcerative Colitis, 2017-2027
  • Figure 15: Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Crohn's Disease, 2017-2027
  • Figure 16: Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Value Share Analysis, by Distribution channel, 2018 and 2027
  • Figure 17: Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Attractiveness, by Distribution channel, 2019-2027
  • Figure 18: Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Hospital Pharmacies, 2017-2027
  • Figure 19: Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Retail Pharmacies, 2017-2027
  • Figure 20: Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Online Pharmacies, 2015-2025
  • Figure 21: Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Value Share Analysis, by Region, 2018 and 2027
  • Figure 22: Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Attractiveness Analysis, by Region, 2019-2027
  • Figure 23: North America IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2019-2027
  • Figure 24: North America IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Value Share Analysis, by Country, 2018 and 2027
  • Figure 25: North America IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Attractiveness Analysis, by Country, 2019-2027
  • Figure 26: North America IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Value Share Analysis, by Drug Class, 2018 and 2027
  • Figure 27: North America IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Value Share Analysis, by Disease Indication, 2018 and 2027
  • Figure 28: North America IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Value Share Analysis, by Distribution Channel, 2018 and 2027
  • Figure 29: North America IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Attractiveness Analysis, by Drug Class, 2019-2027
  • Figure 30: North America IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Attractiveness Analysis, by Disease Indication, 2019-2027
  • Figure 31: North America IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Attractiveness Analysis, by Distribution Channel, 2019-2027
  • Figure 32: Europe IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2019-2027
  • Figure 33: Europe IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
  • Figure 34: Europe IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Attractiveness Analysis, by Country/Sub-region, 2019-2027
  • Figure 35: Europe IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Value Share Analysis, by Drug Class, 2018 and 2027
  • Figure 36: Europe IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Value Share Analysis, by Disease Indication, 2018 and 2027
  • Figure 37: Europe IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Value Share Analysis, by Distribution Channel, 2018 and 2027
  • Figure 38: Europe IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Attractiveness Analysis, by Drug Class, 2019-2027
  • Figure 39: Europe IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Attractiveness Analysis, by Disease Indication, 2019-2027
  • Figure 40: Europe IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Attractiveness Analysis, by Distribution Channel, 2019-2027
  • Figure 41: Asia Pacific IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2019-2027
  • Figure 42: Asia Pacific IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
  • Figure 43: Asia Pacific IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Attractiveness Analysis, by Country/Sub-region, 2019-2027
  • Figure 44: Asia Pacific IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Value Share Analysis, by Drug Class, 2018 and 2027
  • Figure 45: Asia Pacific IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Value Share Analysis, by Disease Indication, 2018 and 2027
  • Figure 46: Asia Pacific IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Value Share Analysis, by Distribution Channel, 2018 and 2027
  • Figure 47: Asia Pacific IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Attractiveness Analysis, by Drug Class, 2019-2027
  • Figure 48: Asia Pacific IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Attractiveness Analysis, by Disease Indication, 2019-2027
  • Figure 49: Asia Pacific IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Attractiveness Analysis, by Distribution Channel, 2019-2027
  • Figure 50: Latin America IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2019-2027
  • Figure 51: Latin America IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
  • Figure 52: Latin America IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Attractiveness Analysis, by Country/Sub-region, 2019-2027
  • Figure 53: Latin America IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Value Share Analysis, by Drug Class, 2018 and 2027
  • Figure 54: Latin America IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Value Share Analysis, by Disease Indication, 2018 and 2027
  • Figure 55: Latin America IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Value Share Analysis, by Distribution Channel, 2018 and 2027
  • Figure 56: Latin America IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Attractiveness Analysis, by Drug Class, 2019-2027
  • Figure 57: Latin America IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Attractiveness Analysis, by Disease Indication, 2019-2027
  • Figure 58: Latin America IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Attractiveness Analysis, by Distribution Channel, 2019-2027
  • Figure 59: Middle East & Africa IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2019-2027
  • Figure 60: Middle East & Africa IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
  • Figure 61: Middle East & Africa IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Attractiveness Analysis, by Country/Sub-region, 2019-2027
  • Figure 62: Middle East & Africa IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Value Share Analysis, by Drug Class, 2018 and 2027
  • Figure 63: Middle East & Africa IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Value Share Analysis, by Disease Indication, 2018 and 2027
  • Figure 64: Middle East & Africa IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Value Share Analysis, by Distribution Channel, 2018 and 2027
  • Figure 65: Middle East & Africa IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Attractiveness Analysis, by Drug Class, 2019-2027
  • Figure 66: Middle East & Africa IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Attractiveness Analysis, by Disease Indication, 2019-2027
  • Figure 67: Middle East & Africa IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Attractiveness Analysis, by Distribution Channel, 2019-2027
  • Figure 68: Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Share Analysis, by Company (2018)
目次

IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market - Scope of the Report

TMR'S report on the global IBD (ulcerative colitis and Crohn's disease) treatment market studies the past as well as current growth trends and opportunities to gain valuable insights of the same indicators for the said market for the forecast period of 2019 to 2027. The report provides the overall market revenue of the global IBD (ulcerative colitis and Crohn's disease) treatment market for the period of 2017-2027, considering 2018 as the base year and 2027 as the forecast year. The report also provides the compound annual growth rate (CAGR) for the global IBD treatment market for the forecast period.

The report has been prepared after extensive research. Primary research involves bulk of the research efforts, wherein, analysts carried out interviews with industry leaders and opinion makers. Extensive secondary research involves referring to key players' product literature, annual reports, press releases, and relevant documents to understand the global IBD (ulcerative colitis and Crohn's disease) treatment market.

Secondary research also includes Internet sources, statistical data from government agencies, websites, and trade associations. Analysts have also employed a combination of the top-down and bottom-up approaches to study various phenomena in the global IBD (ulcerative colitis and Crohn's disease) treatment market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments and sub-segments included in the scope of the study. Additionally, the report sheds light on the changing competitive dynamics in the global IBD (ulcerative colitis and Crohn's disease) treatment market. These indices serve as valuable tools for existing market players as well as for entities interested in participating in the global IBD treatment market. The next section of the global IBD (ulcerative colitis and Crohn's disease) treatment report highlights the USPs, which include disease prevalence: IBD (ulcerative colitis and Crohn's disease) globally, IBD (ulcerative colitis and Crohn's disease) treatment pipeline analysis, and major deals and strategic alliances analysis in the global IBD (ulcerative colitis and Crohn's disease) treatment market.

The report delves into the competitive landscape of the global IBD (ulcerative colitis and Crohn's disease) treatment market. Key players operating in the global IBD treatment market have been identified, and each one of these has been profiled for their distinguishing business attributes. Company overviews, financial standings, recent developments, and SWOT are some of the attributes of the players profiled in the global IBD (ulcerative colitis and Crohn's disease) treatment market report.

Key Questions Answered in Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Report

What is the sales/revenue expected to be generated by IBD (ulcerative colitis and Crohn's disease) treatment products across all the regions during the forecast period?

What are the key trends in the IBD (ulcerative colitis and Crohn's disease) treatment market?

What are the major drivers, restraints, and opportunities in the market?

Which regional market is set to expand at the fastest CAGR during the forecast period?

Which segment will have the highest revenue, globally, in 2027, and which product segment will expand at the fastest CAGR during the forecast period?

Global IBD Treatment Market - Research Objectives and Research Approach

The comprehensive report on the global IBD (ulcerative colitis and Crohn's disease) treatment market begins with an overview of the said market, followed by the scope and objectives of the study. Following this, the report provides detailed explanation of the objectives of this study and healthcare compliances laid down by accredited agencies in the purview of research in the global IBD (ulcerative colitis and Crohn's disease) treatment market. It is followed by a market introduction, market dynamics, and an overview of the global IBD treatment market, which includes TMR's analysis of the market drivers, restraints, and trends affecting the growth of the market. Furthermore, Y-o-Y analysis with elaborate insights have been provided to understand the Y-o-Y trends of the IBD (ulcerative colitis and Crohn's disease) treatment market. The next section of the global IBD (ulcerative colitis and Crohn's disease) treatment report highlights the USPs, including disease prevalence, globally, treatment pipeline analysis, and major deals & strategic alliance analysis in the global IBD (ulcerative colitis and Crohn's disease) treatment market.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section further divided into small sections. The entire report comprises an exhaustive collection of graphs and tables that are appropriately interspersed in the entire compilation. Pictorial representation of actual and projected values of the key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

Revenue generated by key IBD (ulcerative colitis and Crohn's disease) treatment players has been mapped to ascertain the size of the global IBD (ulcerative colitis and Crohn's disease) treatment market in terms of value. The forecasts presented here assess the total revenue generated in the IBD (ulcerative colitis and Crohn's disease) treatment market. In order to provide an accurate forecast, we initiated by sizing up the current IBD (ulcerative colitis and Crohn's disease) treatment market with the help of the parent market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market

4. Market Overview

  • 4.1. Introduction
  • 4.2. Key Industry Developments
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, 2017-2027

5. Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market, Key Insights

  • 5.1. Clinical Trial Pipeline Analysis: IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market
  • 5.2. Disease Prevalence: IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market
  • 5.3. Major Deals & Strategic Alliances Analysis: IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market

6. Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Analysis and Forecast, by Drug Class

  • 6.1. Key Findings
  • 6.2. Introduction
  • 6.3. Market Value (US$ Mn) Forecast, by Drug Class, 2019-2027
    • 6.3.1. TNF Inhibitors
    • 6.3.2. Aminosalicylates
    • 6.3.3. Integrin Antagonists
    • 6.3.4. Corticosteroids
    • 6.3.5. Others
  • 6.4. Market Attractiveness Analysis, by Drug Class

7. Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Analysis and Forecasts, by Disease Indication

  • 7.1. Key Findings
  • 7.2. Introduction
  • 7.3. Market Value (US$ Mn) Forecast, by Disease Indication, 2019-2027
    • 7.3.1. Ulcerative Colitis
    • 7.3.2. Crohn's Disease
  • 7.4. Market Attractiveness Analysis, by Disease Indication

8. Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Analysis and Forecasts, by Distribution Channel

  • 8.1. Key Findings
  • 8.2. Introduction
  • 8.3. Market Value (US$ Mn) Forecast by Distribution Channel, 2019-2027
    • 8.3.1. Hospital Pharmacies
    • 8.3.2. Retail Pharmacies
    • 8.3.3. Online Pharmacies
  • 8.4. Market Attractiveness Analysis, by Distribution Channel

9. Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Analysis and Forecasts, by Region

  • 9.1. Key Findings
  • 9.2. Global Market Scenario
  • 9.3. Market Value (US$ Mn) Forecast, by Region, 2019-2027
    • 9.3.1. North America
    • 9.3.2. Europe
    • 9.3.3. Asia Pacific
    • 9.3.4. Latin America
    • 9.3.5. Middle East & Africa
  • 9.4. Market Attractiveness Analysis, by Region

10. North America IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Analysis and Forecast

  • 10.1. Key Findings
  • 10.2. Market Value (US$ Mn) Forecast, by Country, 2019-2027
    • 10.2.1. U.S.
    • 10.2.2. Canada
  • 10.3. Market Value (US$ Mn) Forecast, by Drug Class, 2019-2027
    • 10.3.1. TNF Inhibitors
    • 10.3.2. Aminosalicylates
    • 10.3.3. Integrin Antagonists
    • 10.3.4. Corticosteroids
    • 10.3.5. Others
  • 10.4. Market Value (US$ Mn) Forecast, by Disease Indication, 2019-2027
    • 10.4.1. Ulcerative Colitis
    • 10.4.2. Crohn's Disease
  • 10.5. Market Value (US$ Mn) Forecast, by Distribution Channel, 2019-2027
    • 10.5.1. Hospital Pharmacies
    • 10.5.2. Retail Pharmacies
    • 10.5.3. Online Pharmacies
  • 10.6. Market Attractiveness Analysis
    • 10.6.1. By Country
    • 10.6.2. By Drug Class
    • 10.6.3. By Disease Indication
    • 10.6.4. By Distribution Channel

11. Europe IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Analysis and Forecast

  • 11.1. Key Findings
  • 11.2. Market Value (US$ Mn) Forecast, by Country/Sub-region, 2019-2027
    • 11.2.1. Germany
    • 11.2.2. U.K.
    • 11.2.3. France
    • 11.2.4. Italy
    • 11.2.5. Spain
    • 11.2.6. Rest of Europe
  • 11.3. Market Value (US$ Mn) Forecast, by Drug Class, 2019-2027
    • 11.3.1. TNF Inhibitors
    • 11.3.2. Aminosalicylates
    • 11.3.3. Integrin Antagonists
    • 11.3.4. Corticosteroids
    • 11.3.5. Others
  • 11.4. Market Value (US$ Mn) Forecast, by Disease Indication, 2019-2027
    • 11.4.1. Ulcerative Colitis
    • 11.4.2. Crohn's Disease
  • 11.5. Market Value (US$ Mn) Forecast, by Distribution Channel, 2019-2027
    • 11.5.1. Hospital Pharmacies
    • 11.5.2. Retail Pharmacies
    • 11.5.3. Online Pharmacies
  • 11.6. Market Attractiveness Analysis
    • 11.6.1. By Country/Sub-region
    • 11.6.2. By Drug Class
    • 11.6.3. By Disease Indication
    • 11.6.4. By Distribution Channel

12. Asia Pacific IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Analysis and Forecast

  • 12.1. Key Findings / Developments
  • 12.2. Market Overview
  • 12.3. Market Value (US$ Mn) Forecast, by Country/Sub-region, 2019-2027
    • 12.3.1. China
    • 12.3.2. India
    • 12.3.3. Japan
    • 12.3.4. Australia & New Zealand
    • 12.3.5. Rest of Asia Pacific
  • 12.4. Market Value (US$ Mn) Forecast, by Drug Class, 2019-2027
    • 12.4.1. TNF Inhibitors
    • 12.4.2. Aminosalicylates
    • 12.4.3. Integrin Antagonists
    • 12.4.4. Corticosteroids
    • 12.4.5. Others
  • 12.5. Market Value (US$ Mn) Forecast, by Disease Indication, 2019-2027
    • 12.5.1. Ulcerative Colitis
    • 12.5.2. Crohn's Disease
  • 12.6. Market Value (US$ Mn) Forecast, by Distribution Channel, 2019-2027
    • 12.6.1. Hospital Pharmacies
    • 12.6.2. Retail Pharmacies
    • 12.6.3. Online Pharmacies
  • 12.7. Market Attractiveness Analysis
    • 12.7.1. By Country/Sub-region
    • 12.7.2. By Drug Class
    • 12.7.3. By Disease Indication
    • 12.7.4. By Distribution Channel

13. Latin America IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Analysis and Forecast

  • 13.1. Key Findings / Developments
  • 13.2. Market Overview
  • 13.3. Market Value (US$ Mn) Forecast, by Country/Sub-region, 2019-2027
    • 13.3.1. Brazil
    • 13.3.2. Mexico
    • 13.3.3. Rest of Latin America
  • 13.4. Market Value (US$ Mn) Forecast, by Drug Class, 2019-2027
    • 13.4.1. TNF Inhibitors
    • 13.4.2. Aminosalicylates
    • 13.4.3. Integrin Antagonists
    • 13.4.4. Corticosteroids
    • 13.4.5. Others
  • 13.5. Market Value (US$ Mn) Forecast, by Disease Indication, 2019-2027
    • 13.5.1. Ulcerative Colitis
    • 13.5.2. Crohn's Disease
  • 13.6. Market Value (US$ Mn) Forecast, by Distribution Channel, 2019-2027
    • 13.6.1. Hospital Pharmacies
    • 13.6.2. Retail Pharmacies
    • 13.6.3. Online Pharmacies
  • 13.7. Market Attractiveness Analysis
    • 13.7.1. By Country/Sub-region
    • 13.7.2. By Drug Class
    • 13.7.3. By Disease Indication
    • 13.7.4. By Distribution Channel

14. Middle East and Africa IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Analysis and Forecast

  • 14.1. Key Findings / Developments
  • 14.2. Market Overview
  • 14.3. Market Value (US$ Mn) Forecast, by Country/Sub-region, 2019-2027
    • 14.3.1. GCC Countries
    • 14.3.2. South Africa
    • 14.3.3. Rest of Middle East and Africa
  • 14.4. Market Value (US$ Mn) Forecast, by Drug Class, 2019-2027
    • 14.4.1. TNF Inhibitors
    • 14.4.2. Aminosalicylates
    • 14.4.3. Integrin Antagonists
    • 14.4.4. Corticosteroids
    • 14.4.5. Others
  • 14.5. Market Value (US$ Mn) Forecast, by Disease Indication, 2019-2027
    • 14.5.1. Ulcerative Colitis
    • 14.5.2. Crohn's Disease
  • 14.6. Market Value (US$ Mn) Forecast, by Distribution Channel, 2019-2027
    • 14.6.1. Hospital Pharmacies
    • 14.6.2. Retail Pharmacies
    • 14.6.3. Online Pharmacies
  • 14.7. Market Attractiveness Analysis
    • 14.7.1. By Country/Sub-region
    • 14.7.2. By Drug Class
    • 14.7.3. By Disease Indication
    • 14.7.4. By Distribution Channel

15. Competition Landscape

  • 15.1. Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Share, by Company, 2018
  • 15.2. Market Player - Competition Matrix (By Tier and Size of companies)
  • 15.3. Company Profiles (Details - Overview, Financials, Recent Developments, Strategy)
    • 15.3.1. Pfizer, Inc.
      • 15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.1.2. Product Portfolio
      • 15.3.1.3. SWOT Analysis
      • 15.3.1.4. Strategic Overview
    • 15.3.2. Janssen Biotech, Inc. (Johnson & Johnson)
      • 15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.2.2. Product Portfolio
      • 15.3.2.3. SWOT Analysis
      • 15.3.2.4. Financial Overview
      • 15.3.2.5. Strategic Overview
    • 15.3.3. Valeant Pharmaceuticals International, Inc.
      • 15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.3.2. Product Portfolio
      • 15.3.3.3. SWOT Analysis
      • 15.3.3.4. Financial Overview
      • 15.3.3.5. Strategic Overview
    • 15.3.4. Allergan plc.
      • 15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.4.2. Product Portfolio
      • 15.3.4.3. SWOT Analysis
      • 15.3.4.4. Financial Overview
      • 15.3.4.5. Strategic Overview
    • 15.3.5. Takeda Pharmaceutical Company Limited.
      • 15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.5.2. Product Portfolio
      • 15.3.5.3. SWOT Analysis
      • 15.3.5.4. Financial Overview
      • 15.3.5.5. Strategic Overview
    • 15.3.6. AbbVie, Inc.
      • 15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.6.2. Product Portfolio
      • 15.3.6.3. SWOT Analysis
      • 15.3.6.4. Financial Overview
      • 15.3.6.5. Strategic Overview
    • 15.3.7. Novartis AG
      • 15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.7.2. Product Portfolio
      • 15.3.7.3. SWOT Analysis
      • 15.3.7.4. Financial Overview
      • 15.3.7.5. Strategic Overview
    • 15.3.8. UCB Inc.
      • 15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.8.2. Product Portfolio
      • 15.3.8.3. SWOT Analysis
      • 15.3.8.4. Financial Overview
      • 15.3.8.5. Strategic Overview
    • 15.3.9. Biogen Inc.
      • 15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.9.2. Product Portfolio
      • 15.3.9.3. SWOT Analysis
      • 15.3.9.4. Financial Overview
      • 15.3.9.5. Strategic Overview